Surprisingly, serum levels of macrophage/monocyte derived CCL3/MIP-1α and CXCL10/IP-10 were significantly decreased in treatment-naïve FD patients (CCL3/MIP-1α: 13.7 [11.2-45.9] pg/ml; CXCL10/IP-10: 19.5 [6.3-126.1] pg/ml) and after ERT initiation (CCL3/MIP-1α: 11.2 [11.2-54.0] pg/ml; CXCL10/IP-10: 16.2 [1.9-217.4] pg/ml) (Figures 4I, M) as compared to the control group of healthy subjects (CCL3/MIP-1α: 34.5 [18.6-218.1] pg/ml; CXCL10/IP-10: 63.4 [16.6-885.1] pg/ml). This evidence concerns the gene CCL3 and Fabry disease.